Academic, Commercial, and Biodefense Case Studies for Collaborative Drug Discovery: Potential for Disrupting Drug Discovery

Bunin, Barry A.; Ekins, Sean

doi:10.1002/9781118778166.ch19

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Occasionally, there is also the role of patients and advocates [8,9] which can add to the collaboration. In areas such as neglected diseases where the funding is limited for drug discovery [10] there is a compelling need to collaborate and this might not be limited to drug discovery alone but also other parts of the research and development enterprise [11]. We have highlighted the need for more-competitive collaboration in the industry [12] and alternative business models for drug discovery that balance collaboration, privacy and security [13], and certainly the shift toward public–private partnerships (PPPs) fulfils that gap [14].…”

Section: Introductionmentioning

confidence: 99%

Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB)

Ekins

Spektor

Clark

et al. 2017

Drug Discovery Today

Self Cite

View full text Add to dashboard Cite

Neglected disease drug discovery is generally poorly funded compared with major diseases and hence there is an increasing focus on collaboration and precompetitive efforts such as public–private partnerships (PPPs). The More Medicines for Tuberculosis (MM4TB) project is one such collaboration funded by the EU with the goal of discovering new drugs for tuberculosis. Collaborative Drug Discovery has provided a commercial web-based platform called CDD Vault which is a hosted collaborative solution for securely sharing diverse chemistry and biology data. Using CDD Vault alongside other commercial and free cheminformatics tools has enabled support of this and other large collaborative projects, aiding drug discovery efforts and fostering collaboration. We will describe CDD's efforts in assisting with the MM4TB project.

show abstract